ORKA
Oruka Therapeutics, Inc.
Stock
$84.52+1.10 (+1.32%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $19M | $1.0M | $4.7M | $14M | $5.0M | $1.8M | $4.2M | $14M | $12M | $7.1M | $5.6M |
| Operating income | −$28M | −$7.3M | −$11M | −$19M | −$9.8M | −$5.8M | −$8.1M | −$19M | −$17M | −$11M | −$9.7M |
| Non-operating income | — | — | — | $13K | $19K | $165K | $154K | $161K | $169K | — | — |
| Pretax income | — | — | — | −$19M | −$9.7M | −$5.6M | −$8.0M | −$19M | −$16M | — | — |
| Taxes | — | — | — | $0 | −$9K | −$167K | −$31K | −$61K | $0 | — | — |
| Net income | −$27M | −$5.3M | −$9.9M | −$19M | −$9.7M | −$5.5M | −$7.9M | −$18M | −$16M | −$11M | −$9.7M |
| Diluted EPS | −$7.28 | −$0.37 | −$0.69 | −$1.39 | −$2.07 | −$4.15 | −$10.31 | −$1.77 | −$1.81 | −$1.82 | −$3.31 |
| Diluted shares | — | 14.4M | 14.4M | 13.9M | 4.7M | 1.3M | 769K | 10.4M | 9.1M | 6.3M | 2.9M |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — | — |